|
1) Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010; 116: e35-40
|
|
|
|
2) Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J Hum Genet. 1998; 43: 2-8
|
|
|
|
|
3) Chun HJ, Zheng L, Ahmad M, at al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immuno-deficiency. Nature. 2002; 419: 395-9
|
|
|
|
|
|
4) Oliveira JB, Bidére N, Niemela JE, et al. NRAS mutation causes a human autoimmune lympho-proliferative syndrome. Proc Natl Acad Sci U S A. 2007; 104: 8953-8
|
|
|
|
|
|
5) Loh ML. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010: 357-62
|
|
|
|
|
|
6) Kitahara M, Koike K, Kurokawa Y, et al. Lupus nephritis in juvenile myelomonocytic leukemia. Clin Nephrol. 1999; 51: 314-8
|
|
|
|
|
|
7) Miyauchi J, Asada M, Sasaki M, et al. Mutations of the N-ras gene in juvenile chronic myelo-genous leukemia. Blood. 1994; 83: 2248-54
|
|
|
|
|
|
8) Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol. 2011; 152: 677-87
|
|
|
|
|
|
9) Takagi M, Shinoda K, Piao J, et al. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood. 2011; 117: 2887-90
|
|
|
|
|
|
10) Niemela JE, Lu L, Fleisher TA, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood. 2011; 117: 2883-6
|
|
|
|
|
|
11) Kawamoto H, Ikawa T, Masuda K, et al. A map for lineage restriction of progenitors during hematopoiesis: the essence of the myeloid-based model. Immunol Rev. 2010; 238: 23-36
|
|
|
|
|
|
12) Matsuda K, Shimada A, Yoshida N, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood. 2007; 109: 5477-80
|
|
|
|
|
|
13) Lenardo MJ, Oliveira JB, Zheng L. et al. ALPS-ten lessons from an international workshop on a genetic disease of apoptosis. Immunity. 2010; 32: 291-5
|
|
|
|
|
|
14) Aoki Y, Niihori T, Narumi Y, et al. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008; 29: 992-1006
|
|
|
|
|
|
15) Choong K, Freedman MH, Chitayat D, et al. Juvenile myelomonocytic leukemia and Noonan syndrome. Pediatr Hematol Oncol. 1999; 21: 523-7
|
|
|
|
|
|
16) Lisbona MP, Moreno M, Orellana C, et al. Noonan syndrome associated with systemic lupus erythematosus. Lupus. 2009; 18: 267-9
|
|
|
|
|
|
17) Mizutani S, Takagi M. Autoimmune phenomena in Noonan syndrome; a possible link with RALD. Blood. e-letter, 1 December 2010
|
|
|
|
|